Nivolumab Fails to Outperform Durvalumab in Stage III Lung Cancer Trial
A phase 3 trial finds nivolumab-based regimens offer no survival advantage over durvalumab for unresectable stage III NSCLC.
Summary
A major randomized phase 3 trial tested whether adding nivolumab — with or without ipilimumab — to standard chemoradiotherapy could improve outcomes over the current standard of care (durvalumab consolidation) in patients with unresectable stage III non-small cell lung cancer. After a median follow-up of 30.5 months, neither nivolumab plus ipilimumab nor nivolumab alone significantly improved progression-free survival or overall survival compared to durvalumab. Notably, both nivolumab-containing regimens produced higher rates of pneumonitis, a serious lung inflammation side effect. These results, published in Nature Cancer, underscore that more than half of patients still progress or die within 18 months on current treatments, and that simply combining or swapping checkpoint inhibitors is insufficient. The field urgently needs novel treatment strategies for this patient population.
Detailed Summary
Unresectable stage III non-small cell lung cancer (NSCLC) remains one of oncology's most pressing challenges. Despite the approval of concurrent chemoradiotherapy followed by durvalumab consolidation as standard of care, more than 50% of patients progress or die within 18 months — a sobering benchmark that has motivated the search for more effective immunotherapy combinations.
This international randomized phase 3 trial (NCT04026412) enrolled adults with untreated, unresectable stage III NSCLC across three arms: nivolumab added to concurrent chemoradiotherapy followed by consolidation with nivolumab plus ipilimumab (Arm A), nivolumab plus chemoradiotherapy followed by nivolumab alone (Arm B), or standard concurrent chemoradiotherapy followed by durvalumab consolidation (Arm C, the comparator). The primary endpoint was progression-free survival (PFS) in Arm A versus Arm C.
At a median follow-up of 30.5 months, the trial's primary endpoint was not met. The hazard ratio for PFS in nivolumab plus ipilimumab versus durvalumab was 0.95 (96% CI: 0.77–1.19; P=0.65), indicating no meaningful difference. Overall survival also showed no improvement, with an HR of 1.12 (95% CI: 0.87–1.43). Similarly, nivolumab alone failed to improve PFS (HR: 0.84) or OS (HR: 0.97) compared to durvalumab.
A clinically important safety signal emerged: both nivolumab-containing arms produced higher rates of pneumonitis compared to durvalumab, raising concerns about tolerability when combining PD-1 inhibitors with radiation.
These findings carry significant implications for oncology practice and drug development. The results effectively confirm durvalumab's position as the standard of care while signaling that PD-1/CTLA-4 dual blockade does not add meaningful benefit in this setting. The authors emphasize the urgent need for genuinely novel treatment approaches — including better patient selection biomarkers, novel targets, and combination strategies beyond checkpoint inhibition — to meaningfully improve outcomes in this difficult-to-treat population.
Key Findings
- Nivolumab plus ipilimumab did not improve PFS vs. durvalumab (HR 0.95, P=0.65) in stage III NSCLC.
- Overall survival showed no benefit with nivolumab-based regimens compared to durvalumab standard of care.
- Nivolumab alone also failed to improve PFS or OS versus durvalumab consolidation.
- Both nivolumab arms produced higher rates of pneumonitis, raising tolerability concerns.
- Over 50% of stage III NSCLC patients still progress or die within 18 months on current standard therapy.
Methodology
This was a randomized, international phase 3 trial (NCT04026412) comparing three treatment arms in adults with untreated unresectable stage III NSCLC. Primary endpoint was PFS in the nivolumab plus ipilimumab arm versus the durvalumab control arm, with OS and safety as secondary endpoints. Median follow-up was 30.5 months.
Study Limitations
The full study data, including subgroup analyses and detailed safety tables, are not available as this summary is based on the abstract only. Industry funding (Bristol Myers Squibb) and extensive author conflicts of interest are present across most investigators. The trial was not designed to detect small absolute differences in survival, and biomarker-based patient selection was not reported in the abstract.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.